S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNS
This week on the Midweek Takeaway, Phil Carroll and Kevin Hornsby are joined by Anthony Tennyson from Solvonis Therapeutics to discuss the company’s recent £1.3 million fundraise and how the new capital will support its three priority clinical programs.
The conversation covers the potential expansion of SVN 001 into Europe, progress towards Phase IIb readiness for SVN 002 in the US, ongoing work with the National Institute on Drug Abuse on SVN 015, and the key regulatory and clinical milestones investors should be watching over the coming months.
Disclaimer & Declaration of Interest
This…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.